stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Operating cash flow
Xeris Biopharma Holdings, Inc.'s operating cash flow for fiscal 2025 was $28.6M, compared with −$37.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $73.6M. Over the past ten years it has ranged from −$104.3M (fiscal 2019) to $28.6M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Xeris Biopharma Holdings, Inc. ranks 29th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $28.6M | — |
| FY2024 | −$37.0M | — |
| FY2023 | −$47.0M | — |
| FY2022 | −$102.9M | — |
| FY2021 | −$95.5M | — |
| FY2020 | −$80.6M | — |
| FY2019 | −$104.3M | — |
| FY2018 | −$56.3M | — |
| FY2017 | −$24.7M | — |
| FY2016 | −$16.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $35.5M | 329.26% |
| Jun 2026 | $8.3M | (16.28%) |
| Mar 2026 | $9.9M | (50.76%) |
| Dec 2025 | $20.0M | 8.74% |
| 35 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | $367.5M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PRGO Perrigo Company plc compare | $240.6M |
| PBH Prestige Consumer Healthcare Inc. compare | $229.8M |
| XERS Xeris Biopharma Holdings, Inc. | $73.6M |
| ALVO Alvotech compare | −$11.8M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$124.8M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$126.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement